Skip to content

For research use only. Not for human consumption.

GLOW 70MG research vial, 3rd Rock Compounds

Front label

Repair & Recovery | Research use only

GLOW 70MG

GLOW Blend is a co-lyophilized research peptide complex combining three of the most extensively studied tissue-remodeling peptides in preclinical literature: 50 mg GHK-Cu (Copper Tripeptide-1), 10 mg BPC-157, and 10 mg TB-500 (Ac-LKKTETQ, the actin-binding fragment of Thymosin β4 ) — totaling 70 mg per vial.

$140

Certificate of analysis available on request

We have not yet published a third-party certificate for this compound. Contact us for the current lot's documentation before ordering.

Quantity

GLOW 70MG

1 vial · $140

  • Third-party HPLC tested
  • Lot-matched certificate
  • Same-day fulfilment before 2pm
  • Shipping 2–4 business days

Identifiers

Mechanism of Action

1. GHK-Cu (50 mg, 71.4% of mass) — Copper Delivery & Gene Modulation

The largest component, GHK-Cu, is the endogenous tripeptide Gly-His-Lys chelated to a Cu(II) ion. It "redox silences" copper to prevent Fenton-reaction toxicity while delivering Cu into cells for use by lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD. Connectivity Map analysis confirmed GHK modulates >4,000 genes, suppressing inflammatory/metastatic signatures and activating repair programs.[9][10] Stimulates collagen I/III, elastin, GAGs, and decorin synthesis with biphasic dose-response peaking near 10⁻⁹ M.[11]

2. BPC-157 (10 mg, 14.3% of mass) — VEGFR2-Akt-eNOS Angiogenic Cascade

BPC-157 binds and internalizes VEGFR2 on endothelial cells, triggering Akt phosphorylation and eNOS activation, yielding nitric oxide production essential for vascular repair (129–152% increased angiogenesis in chick chorioallantoic membrane and rat hind-limb ischemia models).[5] BPC-157 also activates the FAK-paxillin pathway and upregulates growth-hormone-receptor expression on tendon fibroblasts.[13]

3. TB-500 (10 mg, 14.3% of mass) — G-Actin Sequestration & Cell Migration

The LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating polymerization into filamentous actin and enabling cytoskeletal reorganization required for cell motility.[6] TB-500 also engages F1-F0 ATP synthase on endothelial cells (KD ≈ 12 nM), forms a complex with integrin-linked kinase (ILK) and PINCH that activates Akt2, and upregulates MMP-2/MMP-9 to facilitate basement-membrane remodeling during angiogenesis.[14][15] Note: TB-500 lacks the N-terminal Ac-SDKP tetrapeptide of full-length Tβ4 and therefore does not contribute the anti-fibrotic TGF-β-modulating activity of the parent molecule.[16]

Combined Mechanistic Rationale

Repair AxisPrimary DriverMolecular Target
ECM synthesis & gene resetGHK-CuCu(II) delivery; ~31% genome modulated
Angiogenesis & NO signalingBPC-157VEGFR2 → Akt → eNOS
Cell migration & cytoskeletonTB-500G-actin 1:1 binding; ILK-PINCH-Akt2
Antioxidant defenseGHK-Cu, TB-500Nrf2/Keap1; SOD upregulation
Anti-inflammatoryAll threeNF-κB p65 phosphorylation blockade

No published peer-reviewed pharmacokinetic or pharmacodynamic studies have evaluated the 50/10/10 blend as a single co-administered formulation. All mechanistic content is extrapolated from individual-component literature.

Preclinical Research Findings

Laboratory studies using the GLOW combination — or the individual components in parallel — have explored:

  1. Dermal Wound Healing & Re-Epithelialization — GHK-Cu (collagen/elastin synthesis), BPC-157 (granulation tissue formation), and TB-500/Tβ4 (keratinocyte migration) each independently accelerate full-thickness wound closure in rodent models.[11][17][18]
  2. Tendon, Ligament & Skeletal Muscle Repair — BPC-157 has been shown to accelerate Achilles transection healing; TB-500 supports myoblast and tenocyte migration; GHK-Cu modulates MMP/TIMP balance for connective-tissue remodeling.[19][20]
  3. Angiogenesis Models — BPC-157 (VEGFR2-driven) and TB-500/Tβ4 (epicardial progenitor mobilization) have both been documented to enlarge collateral vessel networks in ischemia paradigms.[5][21]
  4. Dermatology & Hair Follicle Research — GHK-Cu enlarges follicle size and prolongs anagen phase in preclinical models; the actin-binding region of Tβ4 (the TB-500 fragment) has been identified as an active site for hair-growth signaling.[22][23]
  5. Anti-Inflammatory & Antioxidant Models — All three components suppress NF-κB activation; GHK-Cu and TB-500 upregulate SOD/catalase; BPC-157 and TB-500 attenuate liver fibrosis in CCl₄/ethanol models.[24][25]
  6. Corneal & Ocular Surface Repair — BPC-157 and the Tβ4-derived peptides have independently demonstrated accelerated corneal epithelial repair in preclinical studies.[26]

Important: every cited study above used individual peptides, not the GLOW combination. Researchers using the blend should design experiments accordingly and not assume that the sum of single-agent effects has been validated in combination.

Safety Profile

Findings summarised above derive from in-vitro and animal studies. No safety profile for human use is established or implied, and none is offered here.

Handle as a laboratory reagent: avoid inhalation and contact, reconstitute under aseptic conditions, and observe the storage conditions below.

For research use only. Not for human consumption.

Shipping and Storage

  • Supplied as lyophilised powder in a sealed vial.
  • Store at 2–8°C (36–46°F). Protect from light.
  • Same-day fulfilment on orders before 2pm; shipping 2–4 business days.
  • For research use only. Not for human consumption.

References

  1. [1]Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. DOI →
  2. [2]Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection. Current Pharmaceutical Design. 2020;26(25):3024-3044.
  3. [3]Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51. DOI →
  4. [4]Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may Prevent Oxidative Stress in Skin. Cosmetics. 2015;2(3):236-247. DOI →
  5. [5]Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. Journal of Molecular Medicine. 2017;95(3):323-333. DOI →
  6. [6]Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:767785. DOI →
  7. [7]U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding. FDA.gov. Updated 2023. fda.gov →
  8. [8]World Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025. wada-ama.org →
  9. [9]Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the human genome to health. BioMed Research International. 2014;2014:151479. DOI →
  10. [10]Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. BioMed Research International. 2015;2015:648108. DOI →
  11. [11]Maquart FX, Pickart L, et al. Stimulation of collagen synthesis by GHK-Cu. FEBS Letters. 1988;238(2):343-346. DOI →
  12. [12]Schlosser N. BPC-157: A Polyproline II Helix Engages SH3 Domains of Src Family Kinases. 2025.
  13. [13]Chang CH, et al. BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077. DOI →
  14. [14]Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. DOI →
  15. [15]Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta 4. The FASEB Journal. 2010;24(7):2144-2151. DOI →
  16. [16]Bock-Marquette I, et al. Thymosin beta-4 denotes new directions for anti-aging therapies. International Immunopharmacology. 2023;116:109741. DOI →
  17. [17]Canapp SO Jr, et al. Topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. 2003;32(6):515-523. DOI →
  18. [18]Philp D, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair. Wound Repair and Regeneration. 2003;11(1):19-24. DOI →
  19. [19]Staresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research. 2003;21(6):976-983. DOI →
  20. [20]Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP Expression. Journal of Aging Science. 2016;4(3):166. DOI →
  21. [21]Smart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. DOI →
  22. [22]Kuceki G, et al. Enhanced hair regrowth with minoxidil-dutasteride-copper peptides for androgenetic alopecia. JAAD International. 2025;20:38-40. DOI →
  23. [23]Goldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429. DOI →
  24. [24]Sever M, et al. BPC 157 counteracts liver fibrosis. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
  25. [25]Shah R, et al. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Liver Injury. Oxidative Medicine and Cellular Longevity. 2018;2018:9630175. DOI →
  26. [26]Sosne G, Dunn SP, Kim C. Thymosin β4 Improves Severe Dry Eye in a Phase 2 Randomized Trial. Cornea. 2015;34(5):491-496. DOI →

Entries without a link have no DOI or PubMed identifier in the source record. The reference is reproduced as given; every link that does appear has been checked and resolves to the work it names.